Cardiology journal最新文献

{"title":"Staphylococcus aureus-related fatal abdominal aortitis case.","authors":"Bojan Miletic, Elefteri Buset, Yves Sutter, Marcus Hesse","doi":"10.5603/cj.104071","DOIUrl":"https://doi.org/10.5603/cj.104071","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 2","pages":"210-211"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter aortic valve implantation reduces plasma concentrations of TMAO and indoxyl sulfate: A prospective, multicenter cohort study.","authors":"Aleksandra Gąsecka, Marcelina Gniot, Bogna Rajewska, Weronika Dykacz, Weronika Kisielewska, Ewelina Błażejowska, Jakub M Zimodro, Marcin Grabowski, Bartosz Rymuza, Zenon Huczek, Janusz Kochman, Radosław Wilimski, Mariusz Kuśmierczyk, Jan Budzianowski, Jarosław Hiczkiewicz, Anna Olasińska-Wiśniewska, Marek Grygier, Krzysztof J Filipiak, Marcin Ufnal","doi":"10.5603/cj.102844","DOIUrl":"10.5603/cj.102844","url":null,"abstract":"<p><strong>Background: </strong>Intestinal microbial metabolites, such as trimethylamine-N-oxide (TMAO) and indoxyl sulfate (IS), have been suggested as markers for the progression of aortic stenosis (AS). However, the impact of transcatheter aortic valve implantation (TAVI) on these intestinal bacterial metabolites has not been evaluated in a multicenter clinical study. The aim of this study was to determine the effect of TAVI on plasma levels of intestinal bacterial metabolites and to assess the predictive value of these metabolites for major adverse cardiovascular events (MACE) following TAVI. M: ETHODS: Consecutive patients with AS referred for TAVI were enrolled in this study. Blood samples were collected one day before TAVI and at hospital discharge. The concentrations of intestinal microbial metabolites were measured using ultra performance liquid chromatograph coupled with a mass spectrometer.</p><p><strong>Results: </strong>Plasma levels of TMAO and IS decreased after TAVI, compared to baseline (p ≤ 0.004 for all). Among 128 patients included in the study, 21 patients (16.4%) developed MACE during the median follow-up time of 404 days. Baseline plasma IS level was higher in patients with MACE, compared to those without MACE (p = 0.001). Increased baseline IS level predicted MACE with 75.0% sensitivity and 74.3% specificity independent of other clinical variables (OR 14.264, 95% CI 3.442-59.117, p < 0.001) and decreased the chance of event-free survival (plog rank < 0.001).</p><p><strong>Conclusions: </strong>Plasma concentrations of TMAO and IS decreased after TAVI, compared to baseline. Elevated plasma IS levels were associated with a 14-fold increase in the odds of post-TAVI MACE during a median follow-up period of 404 days.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"164-174"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Silent cerebral ischemic lesions in ablation-naïve patients with non-valvular atrial fibrillation: Does the pulmonary vein anatomy matter?","authors":"Andrzej Głowniak, Anna Drelich-Zbroja, Adam Tarkowski, Paweł Marzęda, Katarzyna Wojewoda, Katarzyna Wysokińska, Anna Wysocka, Monika Miazga, Anna Jaroszyńska, Krzysztof Kaczmarek, Andrzej Jaroszyński, Michał Orczykowski","doi":"10.5603/cj.99142","DOIUrl":"10.5603/cj.99142","url":null,"abstract":"<p><strong>Background: </strong>Silent cerebral ischemic lesions (SCILs) detected by magnetic resonance imaging (MRI) can precede symptomatic stroke, the risk of which is increased five-fold in atrial fibrillation (AF) patients. In our study, we aimed to evaluate the initial incidence of SCILs in the population of patients referred for ablation due to symptomatic AF and to identify possible risk factors.</p><p><strong>Methods: </strong>A total of 110 patients, with a mean age (SD) of 59.9 (9.4) years, referred for ablation, were included in the study. In all patients, MRI was performed before the procedure to evaluate the incidence of SCILs in the ablation-naïve patients.</p><p><strong>Results: </strong>MRI revealed preexisting SCIL in 81/110 patients (73.6%). Notably, SCILs were found in all patients with CHA₂DS₂-VASc score ≥ 4. In univariable analysis, age (p < 0.001), CHA₂DS₂-VASc score (p = 0.001), hypertension (p = 0.01), and anticoagulation duration (p = 0.023) were identified as significant risk factors for SCILs, while the presence of anatomical variants of left-sided common pulmonary veins trunk (LCPV) had negative prognostic value (p = 0.026). Multivariable logistic regression analysis identified age (p < 0.001) as the risk factor of preexisting SCILs, whereas the presence of LCPV trunk was associated with significantly lower (p = 0.005) SCILs incidence.</p><p><strong>Conclusions: </strong>Silent cerebral ischemic lesions detected in MRI are frequent in the population of patients with non-valvular AF. The incidence of SCILs is higher in patients with long history of arrhythmia and higher CHA₂DS₂-VASc score. The relationship between the anatomy of pulmonary veins and the incidence of SCILs needs further investigation.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"35-42"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and prognostic value of cystatin C in acute coronary syndrome: An up-to-date meta-analysis.","authors":"Michal Pruc, Damian Swieczkowski, Basar Cander, Milosz J Jaguszewski, Sagar Galwankar, Salvatore Di Somma, Fatimah Lateef, Indrani Sardesai, Ayman El-Menyar, Michal Zembala, Jacek Kubica, Togay Evrin, Burak Katipoglu, Zubaid Rafique, Frank William Peacock, Lukasz Szarpak","doi":"10.5603/cj.102453","DOIUrl":"10.5603/cj.102453","url":null,"abstract":"<p><strong>Background: </strong>The role of Cystatin C (CysC) in the diagnosis and prognosis of cardiovascular disease, particularly acute coronary syndrome (ACS), is increasingly significant. The goal of this meta-analysis was to assess the diagnostic and prognostic value of CysC in patients with ACS, as well as its association with major adverse cardiovascular events (MACE), defined as mortality, myocardial infarction, heart failure, and stroke.</p><p><strong>Methods: </strong>The present study is a systematic review and meta-analysis. Using PubMed, Web of Science, Cochrane Library, and Embase, a literature review of cohort and case control studies reporting MACE and using the terms ACS and Cystatin C was conducted, excluding studies published after August 1, 2024. the meta-analysis using a random effects model.</p><p><strong>Results: </strong>CysC concentrations were significantly higher in patients with ACS compared to controls [mean difference (MD) = 0.36, p < 0.001], and in acute myocardial infarction (AMI) vs. unstable angina (MD = 0.18, p < 0.001). No significant differences were observed between ST elevation myocardial infarction (STEMI) and Non-ST elevation myocardial infarction (NSTEMI). Patients with MACE had higher CysC levels than those without (MD = 0.25, p < 0.001). Hospital survivors had lower CysC levels compared to those who died (MD = -0.25, p < 0.001). Higher CysC concentrations were associated with increased risks of MACE, cardiac death, overall mortality, myocardial reinfarction, and stroke, both during hospitalization and beyond.</p><p><strong>Conclusions: </strong>CysC is a promising biomarker for both diagnosis and prognosis in patients with ACS, especially in the context of predicting MACE, mortality and heart failure risk. The use of CysC may improve risk stratification and support therapeutic decision-making in clinical practice.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"142-152"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic potential of increased Klotho and FGF23 protein concentrations after myocardial infarction in patients with acute coronary syndrome.","authors":"Agnieszka Olejnik, Joanna Płonka, Wiktor Kuliczkowski, Andrzej Mysiak, Marek Gierlotka, Iwona D Bil-Lula","doi":"10.5603/cj.98861","DOIUrl":"10.5603/cj.98861","url":null,"abstract":"<p><strong>Background: </strong>Klotho is a transmembrane and secretory protein and acts as a co-receptor for fibroblast growth factor 23 (FGF23). This study aimed to analyse the concentration of Klotho and FGF23 proteins in patients with myocardial infarction (MI).</p><p><strong>Methods: </strong>The study group comprised 129 patients diagnosed with acute coronary syndrome (ACS), who were referred for further invasive diagnostics (MI group). Blood samples were collected at 4 time points: at admission, and 6h, 24h, and between 24-48h post-admission. The criteria for the control subjects (n = 30) were no declaration of MI and ACS (non-MI group). Klotho and FGF23 concentrations in plasma were tested by ELISA at each time point.</p><p><strong>Results: </strong>The concentration of soluble Klotho in the MI group was increased at admission, 6h and 24 h post-admission, and then normalized at 24-48h. Klotho concentration was also significantly increased in patients with ST-segment elevation MI (STEMI) only at admission, in comparison to non-ST-segment elevation MI (NSTEMI). The concentration of FGF23 in the MI group was higher at admission, 6h and 24h post-admission, and continued to increase after 24-48 h. There was an increase in FGF23 concentration in the STEMI group at 24-48h post-admission, in comparison to NSTEMI.</p><p><strong>Conclusions: </strong>The concentrations of Klotho and FGF23 in plasma were higher in patients with MI and changed over time. Thus, Klotho and FGF23 may be recognized as new factors in the diagnosis and/or monitoring of ACS, as well as novel therapeutic targets.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"380-391"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiography-derived index of microcirculatory resistance predicts long-term outcomes in late-presenting patients with ST-segment elevation myocardial infarction.","authors":"You Zhou, Su Li, Yiqing Hu, Dong Huang, Chunfeng Dai, Jinxiang Chen, Muyin Liu, Ming Yin, Youran Li, Hao Lu, ChenGuang Li, Zhangwei Chen, Juying Qian, Junbo Ge","doi":"10.5603/cj.101485","DOIUrl":"10.5603/cj.101485","url":null,"abstract":"<p><strong>Background: </strong>The association between coronary microcirculatory function and long-term outcomes in late-presenting patients with ST-segment elevation myocardial infarction (STEMI) is unclear.</p><p><strong>Methods: </strong>A total of 340 STEMI patients with late presentation (> 12 hours from the onset of symptoms) who underwent delayed percutaneous coronary intervention (PCI) were consecutively recruited from 2016 to 2021. The coronary microvasculature was assessed by angiography-derived index of microcirculatory resistance (caIMR) using commercial software. The primary endpoint was major adverse cardiovascular events (MACE) defined as a composite of all-cause death and myocardial infarction.</p><p><strong>Results: </strong>The median symptom-to-angiography time was 149 hours (interquartile range [IQR], 101-192). The culprit vessels were completely occluded in 120 (35.3%) patients. During the follow-up with a median period of 51 months, MACE occurred in 27 patients (7.9%). After adjusting for risk factors, caIMR > 25 U after PCI was independently associated with an increased incidence of MACE (adjusted hazard ratio, 4.31; 95% confidence interval, 1.92-9.67; p < 0.001). The area under the curve (AUC) for caIMR in predicting MACE was 0.675 (p = 0.020).</p><p><strong>Conclusions: </strong>Our study indicated that caIMR was an important prognostic predictor in late-presenting STEMI patients who underwent delayed PCI. Preservation of coronary microcirculatory function during PCI could provide long-term prognostic benefits.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"357-368"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary cardiac angiosarcoma: an extremely rare entity presenting with palpitations.","authors":"Yueli Wang, Dong Chen, Jingjing Meng, Jiancheng Han, Yihua He","doi":"10.5603/cj.101335","DOIUrl":"https://doi.org/10.5603/cj.101335","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 2","pages":"208-209"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators' viewpoint.","authors":"Jacek Kubica, Piotr Adamski, Robert Gajda, Aldona Kubica, Małgorzata Ostrowska, Gavino Casu, Diana A Gorog, Paul A Gurbel, Tomasz Hajdukiewicz, Miłosz Jaguszewski, Young-Hoon Jeong, Agata Kosobucka-Ozdoba, Zuzana Motovska, Piotr Niezgoda, Maciej Piasecki, Przemysław Podhajski, Paolo Raggi, Uzeyir Rahimov, Jolanta M Siller-Matula, Grzegorz Skonieczny, Łukasz Szarpak, Paweł Szymański, Udaya Tantry, Eliano P Navarese","doi":"10.5603/cj.98323","DOIUrl":"10.5603/cj.98323","url":null,"abstract":"<p><p>According to the ESC guidelines, cangrelor may be considered in P2Y12-inhibitor-naïve acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The aim of this review is to summarize available evidence on the optimal maintenance therapy with P2Y12 receptor inhibitor after cangrelor. Transitioning from cangrelor to a thienopyridine, but not ticagrelor, can be associated with a drug-drug interaction (DDI); therefore, a ticagrelor loading dose (LD) can be given any time before, during, or at the end of a cangrelor infusion, while a LD of clopidogrel or prasugrel should be administered at the time the infusion of cangrelor ends or within 30 minutes before the end of infusion in the case of a LD of prasugrel. Administration of any oral antiplatelet agent at the end of a cangrelor infusion will also result in a transient period of increased platelet reactivity. The inter-individual variability of this period is difficult to predict because it depends on many factors related to the patient and the treatment. In addition, experimental studies indicate that cangrelor may exert a cardioprotective effect beyond the blockade of platelet aggregation. Considering the available data, the potential use of cangrelor in ACS patients goes well beyond the current indications. Furthermore, we believe that it might be prudent to avoid use of thienopyridines during and soon after a cangrelor infusion until conclusive data on the effect of the DDI on the clinical outcome are available. On the other hand, ticagrelor seems to be an optimal oral agent for continuation of P2Y12 inhibition in patients receiving cangrelor infusion.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"83-89"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-coated balloons in percutaneous coronary interventions: existing evidence and emerging hopes.","authors":"Aleksandra Gąsecka, Patryk Pindlowski, Mateusz Szczerba, Jakub M Zimodro, Ewelina Błażejowska, Arkadiusz Pietrasik, Maciej Lesiak, Mario Iannaccone, José P S Henriques, René J van der Schaaf, Janusz Kochman","doi":"10.5603/cj.101393","DOIUrl":"10.5603/cj.101393","url":null,"abstract":"<p><p>Drug-coated balloons (DCB) have been developed as an alternative to drug-eluting stents (DES) as a part of the \"leave nothing behind\" strategy following percutaneous coronary interventions (PCI). DCBs facilitate revascularization and delivery of an antiproliferative agent directly to a coronary artery lesion, without the need for DES implantation. Subsequently, DCBs promote positive vascular remodeling and allow for a shorter duration of dual antiplatelet therapy. Since the first reports on the successful treatment of coronary in-stent restenosis (ISR) with paclitaxel-coated balloon catheters in the year 2006, the use of DCBs has been growing, driven by reports of DCB application to treat ISR, bifurcation lesions, and small vessel disease. Contemporary clinical trials evaluating DCBs in large vessel disease and chronic total occlusions might further expand the indications for this technology. Attention has also been brought to the use of DCBs in patients with diabetes mellitus and acute coronary syndrome, especially those at high bleeding risk. This review aims to discuss the existing evidence and emerging hopes associated with DCBs, including technical aspects of DCB PCI and the use of DCBs in different clinical scenarios.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"308-320"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular sequelae in symptomatic SARS-CoV-2 infection survivors.","authors":"Grzegorz Skonieczny, Marta Skowrońska, Agnieszka Dolacińska, Beata Ratajczak, Patrycja Sulik, Oliwia Doroba, Alicja Kotula, Ewelina Błażejowska, Izabela Staniszewska, Olaf Domaszk, Piotr Pruszczyk","doi":"10.5603/cj.99538","DOIUrl":"10.5603/cj.99538","url":null,"abstract":"<p><strong>Background: </strong>SARS-CoV-2 infection may lead to myocardial and endothelial damage. The present study sought to characterize the cardiovascular sequel in a large group of consecutive patients admitted for out-patient cardiovascular follow-up after a symptomatic COVID-19 infection.</p><p><strong>Methods: </strong>The aims of this study were as follows: to evaluate the presence of post-covid cardiovascular symptoms in an unselected population of outpatients referred to a post-COVID outpatient cardiology clinic and to characterize the long-term abnormalities associated with a more severe COVID-19 infection clinical course. A total of 914 patients were included in this single-center, observational, cross-sectional study, of which 163 were hospitalized and 149 required mechanical ventilation for COVID-19 pneumonia. Patients were analyzed at follow-up according to the care setting during the initial presentation.</p><p><strong>Results: </strong>The median time to follow-up was 126 days. At that time, only 3.5% of patients reported no persistent dyspnea, chest pain, or fatigue on exertion. In a follow-up echocardiographic assessment, patients who required hospitalization showed slight alterations in the pulmonary acceleration time and the tricuspid regurgitation pressure gradient, as well as reduced exercise tolerance during treadmill exercise testing when compared to patients with a benign clinical course. 24-hour Holter EKG monitoring or 24-hour blood pressure monitoring did not identify significant differences between the analyzed subgroups.</p><p><strong>Conclusions: </strong>The current study reports on an association between COVID-19 severity and the presence of cardiovascular alterations at follow-up. A simple diagnostic protocol, comprising an exercise treadmill test and transthoracic echocardiography is useful in identifying patients who may benefit from regular, structured cardiovascular medical care.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}